This article is more than 5 years old. Information may no longer be current.

Toric phakic IOL an option in keratoconus

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

BOSTON — The toric version of STAAR Surgical Co.'s Visian ICL, currently in U.S. clinical trials, is showing potential for treating patients with myopic astigmatism, and it may also have applications for some patients with keratoconus, according to a surgeon speaking here.

John A. Vukich, MD, discussed phakic IOLs during a presentation at the American Society of Cataract and Refractive Surgery Summer Refractive Congress. He said early clinical results with the Visian Toric ICL (TICL) show good results at 1 year.

"The intraocular option is growing as a reasonable choice we can offer our patients," he said.

The Visian TICL may also have potential as a treatment for patients with stable keratoconus, he suggested. In a study of 19 eyes of 15 patients with keratoconus, researchers found that best-corrected visual acuity improved following implantation of the lens.

Preoperatively, spherical equivalent was -2 D to -6 D in 36.8% of eyes, -6.1 D to -10 D in 42.1% of eyes, -10.1 D to -14 D in 10.5%, and -14.1 D to -19 D in 10.5%. Postoperatively, 44% of patients gained one line of Snellen visual acuity, 19% gained two lines, and 31% had no loss or gain of BCVA.